JPRN-UMIN000038464已完成未知
Phase I/II study of docetaxel and S-1 in previously treated patients with advanced non-small cell lung cancer - LOGIK0408
Clinical Research Support Center Kyushu0 个研究点目标入组 39 人开始时间: 2019年11月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 39
研究概览
简要总结
The median period of follow-up was 8 months(range, 1~39 months). The response to treatment was as follows: complete response, 0; partial response, 3; stable disease, 24; PD, 5; and no effect, 7.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •active infection, massive ascites or pleural effusion symptomatic brain metastasis uncontrollable diabetes mellitus severe comorbidity such as heart disease or renal disease, interstitial pneumonia, watery diarrhea, active concomitant malignancy pregnancy or lactation, or other medical problems severe enough to prevent compliance with the protocol Both of the following conditions were necessary an interval of at least 4 weeks after the end of final therapy and recovery from the previous treatment
研究者
相似试验
已完成
1 期
PhaseI/II study of Docetaxel/S-1 with radiation for unresectable and/or recurrent esophageal cancerunresectyable esophageal cancer, recurrent esophageal cancerJPRN-UMIN000004349Department of Digestive surgery, Kawasaki Medical University30
已完成
2 期
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart FailureDiastolic Heart FailureNCT00303498Pfizer200
进行中（未招募）
不适用
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion. - STP-LYM-01-V01EUCTR2009-014641-88-DEMedizinische Fakultaet der Technischen Universitaet Muenchen
进行中（未招募）
不适用
Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemiarelapsed or refractory Chronic Lymphocytic LeukemiaMedDRA version: 9.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaEUCTR2006-006694-24-DEFresenius Biotech GmbH
尚未招募
1 期
VSSPs in renal carcinoma.VaccinesInjections, SubcutaneousCarcinoma, Renal CellAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsKidney DiseasesUrologic DiseasesUrogenital Diseasesmetastatic renal carcinomaAdjuvants, ImmunologicImmunomodulating AgentsRPCEC00000425Center of Molecular Immunology (CIM)70